Mineralys Therapeutics, Common Stock Shares Owned By Institutions
| MLYS Stock | 9.68 0.92 10.50% |
Mineralys Therapeutics, Common fundamentals help investors to digest information that contributes to Mineralys Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Mineralys Stock. The fundamental analysis module provides a way to measure Mineralys Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mineralys Therapeutics, stock.
Mineralys |
Mineralys Therapeutics, Common Company Shares Owned By Institutions Analysis
Mineralys Therapeutics,'s Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Mineralys Therapeutics, Shares Owned By Institutions | 97.48 % |
Most of Mineralys Therapeutics,'s fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mineralys Therapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 97% of Mineralys Therapeutics, Common are shares owned by institutions. This is 118.37% higher than that of the Biotechnology sector and 105.22% higher than that of the Health Care industry. The shares owned by institutions for all United States stocks is 148.61% lower than that of the firm.
Mineralys Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mineralys Therapeutics,'s direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mineralys Therapeutics, could also be used in its relative valuation, which is a method of valuing Mineralys Therapeutics, by comparing valuation metrics of similar companies.Mineralys Therapeutics, is currently under evaluation in shares owned by institutions category among its peers.
Mineralys Fundamentals
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | 262.79 M | ||||
| Shares Outstanding | 49.84 M | ||||
| Shares Owned By Insiders | 2.52 % | ||||
| Shares Owned By Institutions | 97.48 % | ||||
| Number Of Shares Shorted | 1.86 M | ||||
| Price To Book | 2.41 X | ||||
| EBITDA | (192.4 M) | ||||
| Net Income | (177.81 M) | ||||
| Total Debt | 14.65 M | ||||
| Book Value Per Share | 3.84 X | ||||
| Cash Flow From Operations | (166.31 M) | ||||
| Short Ratio | 7.36 X | ||||
| Earnings Per Share | (3.66) X | ||||
| Target Price | 32.0 | ||||
| Number Of Employees | 51 | ||||
| Beta | 1.45 | ||||
| Market Capitalization | 436.56 M | ||||
| Total Asset | 205.9 M | ||||
| Retained Earnings | (302.52 M) | ||||
| Working Capital | 190.71 M | ||||
| Net Asset | 205.9 M |
About Mineralys Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mineralys Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mineralys Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mineralys Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.